Oppenheimer Assumes Ligand Pharma (LGND) at Outperform
Oppenheimer analyst Leland Gershell assumes coverage on Ligand Pharma (NASDAQ ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
